title: Protective activity of inhaled frusemide against immunological respiratory changes and mediator release in guinea-pigs.
abstract: The antianaphylactic activity of inhaled frusemide was studied in ovalbumin-sensitized guinea-pigs. The exposure of the animals to frusemide aerosol (1% solution for 20 min) attenuated the respiratory response to ovalbumin challenge (aerosol 1% solution) and was associated with a significant reduction of blood histamine (70%; P less than 0.01) and thromboxane-B2 (35%; P less than 0.01) compared to control animals. Similar results were obtained in isolated lungs perfused via the trachea excised from ovalbumin-sensitized guinea-pigs exposed to frusemide aerosol (1% solution for 20 min). In this series of experiments frusemide significantly prevented the increase in tracheal perfusion pressure (45%; P less than 0.01) and the concomitant release into the pulmonary effluent of both histamine (75%; P less than 0.01) and thromboxane-B2 (39%; P less than 0.01). In another series of experiments, frusemide (1 x 10(-4) M) significantly reduced the immune release of histamine from mast cells of ovalbumin-sensitized rats. The inhibitory activity of frusemide was in the same range of potency (66%; P less than 0.01) as that of disodium cromoglycate (1 x 10(-4) M). These data taken together indicate that frusemide when given by inhalation prevents histamine release secondary to antigen-antibody reaction.
authors.affiliation: Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Berti
authors.forename: G
authors.initials: G
authors.lastname: Rossoni
authors.forename: G
authors.initials: G
authors.lastname: Zuccari
authors.forename: A
authors.initials: A
authors.lastname: Buschi
authors.forename: M
authors.initials: M
authors.lastname: Robuschi
authors.forename: L M
authors.initials: LM
authors.lastname: Villa
authors.forename: O
authors.initials: O
authors.lastname: Caratozzolo
mesh_terms: D000280:Administration, Inhalation; D000707:Anaphylaxis / Q000517:prevention & control*; D000818:Animals; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use*; D006168:Guinea Pigs; D006632:Histamine / Q000097:blood; D006636:Histamine Release / Q000187:drug effects; D007114:Immunization; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008297:Male; D010047:Ovalbumin / Q000276:immunology / Q000633:toxicity; D011863:Radioimmunoassay; D051381:Rats; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D013929:Thromboxane B2; D005665:Furosemide; D006632:Histamine; D010047:Ovalbumin